Study Design, Setting, and Participants
This prospective case series was performed at the University of Pennsylvania following Institutional Review Board approval. Patients were eligible for this study if they were >18 years old and undergoing TORS resection of a biopsy-proven p16-positive OPSCCC with or without neck dissection between February 2016 and January 2018. All patients provided informed consent. Patients with a history of radiation, chemotherapy, or recurrent malignancy were excluded.